๐ฐ Biocon Pharma News
Page 2 - Biocon Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biocon Pharma. Real-time updates on events, politics, business and more.
February 18, 2023
Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).
February 18, 2023
USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to โFailed Impurities/Degradation Specifications: High Out Of Specification degradation resultsโ.
October 1, 2022
On Friday, Celgene Corporation filed a complaint in the District of New Jersey. The case was filed against Biocon Pharma Inc. The action focuses on
February 8, 2022
Stocks in news: Adani Wilmar, TVS Motors, Castrol India, Biocon, L&T, Minda Industries and more
December 3, 2021
Stocks in news: ONGC, Bharat Dynamics, ABB India, Biocon, Canara Bank, Ujjivan Financial and more
December 3, 2021
Stocks in the news, big brokerage calls of the day, complete trade setup and much more!
December 2, 2021
The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180 mg and 360 mg strengths.
December 2, 2021
Biotechnology major Biocon on Thursday said its unit has received approval from the US health regulator to market a generic product. Biocon Pharma, a subsidiary of the company, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolic Acid, the company said in a regulatory filing. The product is
May 17, 2021
Health your username 8 hours ago On Friday, Celgene Corporation filed a complaint in the District of New Jersey. The case was filed against Biocon Pharma Inc. The action focuses on potential patent infringement regarding ten patents held by Celgene which would potentially be infringed upon by a potential generic drug created by Biocon. The patents address methods for treating cancer, specifically multiple myeloma and related blood and bone marrow cancers. The patents resulted in a drug regimen...
April 12, 2021
Biocon Pharma Limited receives GMP compliance certificate from MHRA, UK Posted On: 2021-04-11 20:08:53 (Time Zone: Arizona, USA) Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru. The certificate, which includes manufacturing and packaging of tablets...